Cilostazol After Lower Extremity Arterial Revascularization Trial
Status:
Terminated
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm
(Cilostazol) and tenwill be randomized to the control group. Patients randomized to the
treatment arm will receive Cilostazol for 90 days. The primary purpose of this study is to
collect quality of life data on patients undergoing peripheral revascularization in order to
determine the sample size required to adequately power a trial of Cilostazol versus usual
care without Cilostazol and its effect on quality of life.